The technology uses a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker to prevent the formation of primer-dimers.
EASI-Genomics was launched earlier this year to provide free access to NGS technologies and genomic services to researchers from industry and academia.
LGC said the acquisition will improve its position across the clinical quality control tools market and increase its proficiency testing offerings.
CoPrimers use a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker, which prevents the formation of primer-dimers.
The firm has been piecing together a collection of acquisitions over recent years that expand its presence in the genomics market, particularly custom oligos.
LGC said that the acquisition will increase its presence in the nucleic acid market, in addition to its previous acquisitions in the last few years.
The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.
London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.
LGC will offer NuGen's single-primer enrichment technology for next-generation sequencing target enrichment.
LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.